340
Views
27
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

, , , , , , & show all
Pages 1848-1855 | Received 05 Jun 2015, Accepted 20 Oct 2015, Published online: 09 Feb 2016
Supplemental material

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Download Zip (8.5 MB)

Supplemental Table I. Most Common Drug-Related Treatment-Emergent Adverse Events Occurring in ≥ 5% of Patients (Safety Analysis Set; n=41).

Download MS Word (38.5 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.